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786-5 Radlofrequency Cetheter Ablation of Ventricular
Tachycardias Using a New Non-Fluoroscopic
Mapping Technique: First Results
J.L.R.M. Smeets 1, S. Ben-Haim 2, L.-M. Rodriguez 1,C. Timmermans 1,
“,J.J. wellen~ I. I A~demjc HOSpitd Maastricht, The Netherlands,
2 TecfrrrlonUniversity F/aifa, /srae/
The results of radiofrequency (RF) catheter (C) ablation of ventricular tachy-
cadias (VT) are still disappointing. This is caused by several factors: RF
creates small lesions, the reentrant circuit can be located Intramurally, posi-
tioning of C may be difficult, not accurate and hard to reproduce. In this study
we used deflectable C which can be located in a low electromagnetic field
using the CartoT”system. In 6 pts (age 2*76) non fluoroscopic mapping was
performed of VToriginating in the left ventricle. Etiology: idiopathic (1 pt) old
myooardial infarction (5 pts: Inferior in 3, anterior in 1 and anterior/inferior in 1
pt). In 4 pfs one, in 1 pt 2 and in another pt 3 VT morphologies were present.
Results: In one pt VT with 3 VT morphologies only an incomplete map
could be made, so no RF energy was applied. In 5 pte a 3 dimensional map
showedearfy breakthrough in the infero-septal (2), Infero-baso septal (2)
and posterior-lateral area (l). FfF-ablation successfully eliminated VT in 4
pts with 1-5 RF applications. In the remaining pt RF could not terminate VT.
Theareaof endocardial (END) breakthrough was broad (>1 cm), whereas in
the others earfiest END activation araa was narrow. One RF procedura was
oompiloated by a AV Block.
Cone/us/ens: 1) In 5/6 pts complete electroanatomical maps of the left
ventricle during VT could be generated. 2) Guiding by the maps 4/5 VT could
be successfully ablated. 3) RFablation was successful in this limited number
of pts if the map showed a relatively small area of END breakthrough.
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El7866 Entrainment Mapping and Radiofrequency Ablation
of Ventricular Tachycardia In Right Ventricular
Dysplasia
K.E. Ellison, P.L. Friedman, LJ. Ganz, W.G. Stevenson. Brigham and
Women’s Hospiral, Boston, MA, USA
Ventricular tachycardias (VTa) in rightventriculardysplasia(RVD) hava not
been well characterized. The purpose of this study was to determine if
entrainment mapping techniques and predictors of successful ablation sites
previously tested for coronary VT apply to RVD. Mapping of 11 VTSin 4 pts
was performed. At60 sites pacing entrainad VTand RFwas applied to assess
acute termination of VT. Sites were classified as Exit, Central/Proximal (CP),
Inner Loop (IL), Outer Loop (OL) and Bystander by entrainment criteria as
previously described.
Site AcuteTerm “/.
Exit 19 4 21
CP 5 2 40
IL 2 1 50
OL 20 4 20
Bystander 14 2 14
RF acutely terminated VT (acute term) at 13 sites. Acute term at an
exit aite waa followed by absence of inducible VT. VT was often inducible
again when awte term occurred at other types of sites. In two pts RF at a
single site abolished two VTa. In one pt VT was abolished by Ieaionsguided
by pacemapping during sinus rhythm. Thus 7 of 11 VTSwere successfully
ablated and no longer inducible at the end of the study. of these 7 VTS,2
were in the RV outflow tract and the other 5 were adjacent to the tricuspid
annulua. One VT was modified to a longer cycle length. Three VTs were
not ablated or modified. In conclusion entrainment mapping techniques are
uaeful for guiding of RF ablation of VT in RVD. A single region can give rise
to more than one morphology of VT.
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m7871 Older Patients in CARE Benefit from Pravastatin
Post Myocardial Infarction
S.J. Lewis, J, Mitchell, C, East, S.P.Glasser, J. Grant, D,E, Johnstone,
S. Ken, R, Letterer, M. Limacher, G.C. Timmis, L. Moye, J. Rouleau,
M.A. Pfefter, F.M.Sacks, E. Braunwald for the CARE Investigators. Pod/and
Cardiovascular Institute, Portland, Oregon, USA, Legacy Research,
Portland, Oragon, USA
Cholesterol and Recurrent Events (CARE) was a secondary prevention trial
evaluating the benefit of aggressive cholesterol lowering with pravastatin
in post Ml patients with average cholesterol (<240 mg/dl), A prospective
eecondary analysis of CARE was to examine the efficacy in a group of older
(>65) patienta with CHD. At baseline there were 3043 younger (Y) patients
s 65 (54.7 mean), 1116older (0) >65 (69.4 mean). Analysis revealed fewer
currant smokers,ever smokers, and diabetes, but more hypertension Inolder
patients**. Baseline lipids were not different: TC (mg/dl) Y 208.8,0 206; LDL
Y 136.8, 0 138.1; HDL Y 38.4, 040.1, and the pravastatin effect on lipids
at 60 months was similar in older verses younger patients: TC Y 175,2, 0
188.1; LDL Y 100.1, 0 93.4; HDL Y 43.3, 044.3. Both Y and O benefit
from treatment showing risk reduction in endpoints as follows: CHD death or
confirmed Ml Y 19% (NS), O 32%*; CABG Y 17% (NS), O 44%*; PTCA Y
25%*, O 12% (NS); CABG + PTCA Y 25%*, O 35%*; CVA Y 22% (NS), O
40% (NS); combined cardiovascular event endpoint, Y 21%*, O 30%”. This
study demonstrates that despite average lipid levels older patients with CHD
show strong benefit fmm lipid treatment with pravastatin, (*significant, p <
0.05, ** significant, p < 0.001)
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Channel Antagonist Use after Myocardial infarction
J. Leitch, P.McElduff, A. Dobson, R. Heller. Urriversityof Newcastle,
Nekvcast/e,Austra/ia
We evaluated the risk of death and repeat myocardial infarction (Ml) asso-
ciated with the use of calcium antagonists (CA) following Ml in a population
based cohort study associated with the MONICA Project. Patients with Ml
were interviewed in hospital and medical records reviewad. The main out-
comes were time to repeat Ml ancf/orcardiac death and all cause mortality.
Risk ratios were adjusted for age, sex, Ml severity, comorbid conditions and
other drug use.
There were 923 patients treated with CA, 1001 treated with p-blockers
(BB) and 1348 using neither BB nor CA at the time of hospital discharga
after suspected Ml from 1988 to 1994. Compared to patienta discharged on
BB, patients discharged on CA were more likely to have another Ml and/or
cardiac death (rick ratio 1.5 95% Cl 1.2-1.9), cardiac death (risk ratio 1.7,
Cl 1.0-2.7) and death from all causes (risk ratio 1.7, Cl 1.1-2.6). Compared
to patienta given neither BB nor CA, patients given diltiazem (risk ratio 1.4,
Cl 1.1-1.7) and nifadipine (risk ratio 1.6, Cl 1.1-2.4) were at increased risk
of recurrent euspected Ml but not of cardiac death (risk ratios 0.9 [0.4-2.1]
and 0.9 [0.8-1.3], respectively)or all cause mortality (risk ratios 1.0 [0.5-2.1]
and 1.0 [0.7-1 .4]). Risks were not substantially altered when patients taking
other cardiac drugs were excluded. The fisk of Ml and/or cardiac death was
1.6 (Cl 1.2-2.1) for patients given CA alone compared to those given only
BB. Thus, these community based data are consistent with the trial evidence
of the relative benefits of BB and CAafter Ml. Whenever possible, BB should
be usad in preference to CA after myocardial infarction.
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~1 Wfithdrawa,~fCa@qxi,,Afterl.ong-termTreatment,
Increases Ischemic Eventa in Peat-Myocardial
infarction Patienta
A.F.M.van den Heuvel, W.H. van Gilst, D.J. van Veldhuisen, R.J.M. de
Vnes, P.H.J.M. Dunselman, J.H, Kingma for the CATS-investigatore,
Groningen, The Netherlands
ACE-inhibition may have anti-ischemic effects, but whether withdrawal of
these druga mayleadto increased (rebound) ischemia, is unknown. We stud-
iad 207 patients (94 patients on captopril, 113patients on placebo). Captopril,
25 mg TID, was started <24 hr after myocardial infarction, One year double
blind medication, was followed by 1 month single-blind placebo treatment.
